Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

被引：487

作者：

Barker, AJ ^{[1
]}

Gibson, KH ^{[1
]}

Grundy, W ^{[1
]}

Godfrey, AA ^{[1
]}

Barlow, JJ ^{[1
]}

Healy, MP ^{[1
]}

Woodburn, JR ^{[1
]}

Ashton, SE ^{[1
]}

Curry, BJ ^{[1
]}

Scarlett, L ^{[1
]}

Henthorn, L ^{[1
]}

Richards, L ^{[1
]}

机构：

[1] AstraZeneca, Canc & Infect Res, Macclesfield SK10 4TG, Cheshire, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2001年 / 11卷 / 14期

关键词：

D O I：

10.1016/S0960-894X(01)00344-4

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：1911 / 1914

页数：4

共 50 条

[1] Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers
Helen Swaisland
Alison Laight
Lesley Stafford
Helen Jones
Charles Morris
Aaron Dane
Roger Yates
Clinical Pharmacokinetics, 2001, 40 : 297 - 306
[2] Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
Swaisland, H
Laight, A
Stafford, L
Jones, H
Morris, C
Dane, A
Yates, R
CLINICAL PHARMACOKINETICS, 2001, 40 (04) : 297 - 306
[3] ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy
Wakeling, AE
Guy, SP
Woodburn, JR
Ashton, SE
Curry, BJ
Barker, AJ
Gibson, KH
CANCER RESEARCH, 2002, 62 (20) : 5749 - 5754
[4] Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839
Albanell, J
Rojo, F
Baselga, J
SEMINARS IN ONCOLOGY, 2001, 28 (05) : 56 - 66
[5] Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
Ciardiello, F
Caputo, R
Bianco, R
Damiano, V
Fentanini, G
Cuccato, S
De Placido, S
Bianco, AR
Tortora, G
CLINICAL CANCER RESEARCH, 2001, 7 (05) : 1459 - 1465
[6] ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation
Friess, H
Li, JS
Buchler, MW
Korc, M
Kleeff, J
GASTROENTEROLOGY, 2004, 126 (04) : A653 - A653
[7] Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (iressa)
Bianco, C
Tortora, G
Bianco, R
Caputo, R
Veneziani, BM
Caputo, R
Damiano, V
Troiani, T
Fontanini, G
Raben, D
Pepe, S
Bianco, AR
Ciardiello, F
CLINICAL CANCER RESEARCH, 2002, 8 (10) : 3250 - 3258
[8] Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation
Li, JS
Kleeff, J
Giese, N
Büchler, MW
Korc, M
Friess, H
INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 25 (01) : 203 - 210
[9] Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
Maddineni, SB
Sangar, VK
Hendry, JH
Margison, GP
Clarke, NW
BRITISH JOURNAL OF CANCER, 2005, 92 (01) : 125 - 130
[10] ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase
Hirata, A
Ogawa, S
Kometani, T
Kuwano, T
Naito, S
Kuwano, M
Ono, M
CANCER RESEARCH, 2002, 62 (09) : 2554 - 2560

← 1 2 3 4 5 →